Spots Global Cancer Trial Database for carcinoma, hepatocellular
Every month we try and update this database with for carcinoma, hepatocellular cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Proteomic Analysis of Human Hepatocellular Carcinoma | NCT01177631 | Carcinoma, Hepa... | Operation | 18 Years - 75 Years | Far Eastern Memorial Hospital | |
| Impact of C-arm CT in Patients With HCC Undergoing TACE: Optimal Imaging Guidance | NCT00926536 | Carcinoma, Hepa... | C-arm CT + DSA ... DSA only | 18 Years - | Stanford University | |
| DCE-MRI for Assessment of Response to TACE of HCC | NCT02878109 | Carcinoma, Hepa... | Post-treatment ... Pre-treatment p... | 18 Years - | Centre hospitalier de l'Université de Montréal (CHUM) | |
| A Study of Lenvatinib Plus Nivolumab in Participants With Hepatocellular Carcinoma | NCT03418922 | Carcinoma, Hepa... | Lenvatinib Nivolumab | 20 Years - | Eisai Inc. | |
| A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | NCT04487067 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients | NCT00470340 | Liver Neoplasms Liver Cirrhosis Carcinoma, Hepa... Recurrence Neoplasm Recurr... | Oxaliplatin, ge... | 18 Years - 75 Years | Assistance Publique - Hôpitaux de Paris | |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors | NCT04660929 | HER2-positive Adenocarcinoma Bile Duct Cance... Biliary Tract C... Bladder Cancer Breast Cancer Breast Neoplasm Carcinoma, Duct... Carcinoma, Hepa... Cancer Lung Cancer, No... Carcinoma, Ovar... Carcinoma, Smal... Carcinoma, Squa... Carcinoma, Tran... Colorectal Canc... Esophagogastric... Inflammatory Br... Stomach Neoplas... Malignant Neopl... Ovarian Neoplas... Pancreatic Canc... HER2-positive S... HER2-positive B... HER2-positive G... HER-2 Protein O... HER-2 Gene Ampl... Prostate Cancer Head and Neck C... Endometrial Can... Lung Cancer, Sm... | CT-0508 Pembrolizumab | 18 Years - | Carisma Therapeutics Inc | |
| Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria | NCT01141478 | Carcinoma, Hepa... | Proton Beam Rad... Sorafenib | 18 Years - 80 Years | Loma Linda University | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| Transarterial Embolization Alone Versus Drug-Eluting Beads Chemoembolization for Hepatocellular Carcinoma | NCT04803019 | Carcinoma, Hepa... | DEB-TACE TAE | 18 Years - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer | NCT01722175 | Carcinoma, Hepa... | ALPPS surgery PVO surgery | 18 Years - | Washington University School of Medicine | |
| Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | NCT00576056 | Carcinoma, Hepa... | Sorafenib TACE | 18 Years - 100 Years | University of Pittsburgh | |
| Adjuvant Chemotherapy With FOLFOX in HCC Patients After Resection | NCT02738697 | Carcinoma, Hepa... | Adjuvant chemot... Follow-up | 18 Years - 75 Years | Sun Yat-sen University | |
| Endoarterial Treatment in Combination With Percutaneous Thermoablation for Medium-sized and Oligonodular Hepatocellular Carcinomas | NCT04172194 | Carcinoma, Hepa... | 19 Years - | Centre Hospitalier Universitaire de Nice | ||
| Treatment for Patients With Multiple Hepatocellular Carcinomas Based on the NDR Scoring System | NCT02525952 | Hepatocellular ... | Hepatectomy TACE | 18 Years - 70 Years | Eastern Hepatobiliary Surgery Hospital | |
| A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | NCT01171651 | Carcinoma, Hepa... | JX-594 followed... | 18 Years - | SillaJen, Inc. | |
| Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC) | NCT01915589 | Carcinoma, Hepa... | Refametinib (BA... | 18 Years - | Bayer | |
| A Study of GPC3 Redirected Autologous T Cells for Advanced HCC | NCT02715362 | Carcinoma, Hepa... | TAI-GPC3-CART c... | 18 Years - 69 Years | Shanghai GeneChem Co., Ltd. | |
| Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | NCT01214343 | Advanced Hepato... Carcinoma Carcinoma, Hepa... Liver Neoplasms Neoplasms | Sorafenib with ... Sorafenib | 20 Years - | Ministry of Health, Labour and Welfare, Japan | |
| A Study to Evaluate Efficacy and Safety of TheraSphere and Resection Combination Therapy in Patients With Single Large ((> 5cm, Long Diameter ) Hepatocellular Carcinoma : Exploratory Trial | NCT05038397 | Carcinoma, Hepa... | Theraspere | 19 Years - | MedicalExcellence | |
| Chemoembolisation of Non Resectable, Non Metastatic Hepatocellular Carcinomas | NCT01040559 | Carcinoma, Hepa... | idarubicin | 18 Years - | Centre Hospitalier Universitaire Dijon | |
| A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista | NCT04487067 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Regulatory Post Marketing Surveillance Study on Nexavar® | NCT01012011 | Carcinoma, Hepa... Carcinoma, Rena... | Sorafenib (Nexa... | 20 Years - 91 Years | Bayer | |
| A National Registry of Patients With Hepatocellular Carcinoma | NCT00178867 | Carcinoma, Hepa... | - | Vanderbilt University | ||
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma | NCT03572582 | Carcinoma, Hepa... Hepatic Carcino... Hepatocellular ... | Nivolumab TACE | 18 Years - | AIO-Studien-gGmbH | |
| Meclizine for Hepatocellular Carcinoma | NCT03253289 | Carcinoma, Hepa... | Meclizine Oral ... | 18 Years - | Baylor College of Medicine | |
| A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation | NCT04102098 | Carcinoma, Hepa... | Atezolizumab Bevacizumab | 18 Years - | Hoffmann-La Roche | |
| Prospective Surveillance for Very Early Hepatocellular Carcinoma | NCT03588442 | Carcinoma, Hepa... | 30 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | ||
| Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation | NCT00080236 | Liver Transplan... Hepatitis Cholestasis Carcinoma, Hepa... | IDN-6556 Placebo | 18 Years - | Conatus Pharmaceuticals Inc. | |
| Needle Guiding Robot for Radiofrequency Ablation: Safety and Efficacy Study on Hepatocellular Carcinoma Patients | NCT03005756 | Carcinoma, Hepa... | Needle guiding ... | 19 Years - 80 Years | Asan Medical Center | |
| A Study Comparing Radiofrequency Ablation and Hepatic Resection for Hepatocellular Carcinoma | NCT02482909 | Carcinoma, Hepa... | Hepatic resecti... Radiofrequency ... | 20 Years - 70 Years | Seoul National University Hospital | |
| Phase I Study of Image-Guided Radiation Concurrent With Double-Agent Chemotherapy for Hepatocellular Carcinoma | NCT02403544 | Carcinoma, Hepa... | IGRT Capecitabine Oxaliplatin | 18 Years - 65 Years | ChineseAMS | |
| Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) | NCT04976634 | Carcinoma, Hepa... Colorectal Neop... Pancreatic Duct... Biliary Tract N... Endometrial Neo... Esophageal Neop... | Pembrolizumab Belzutifan Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer | NCT00563095 | Carcinoma, Hepa... | Transcatheter A... Transcatheter A... | 18 Years - | Hospital Authority, Hong Kong | |
| Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment | NCT03389126 | Carcinoma, Hepa... | Avelumab | 18 Years - | Seoul National University Hospital | |
| RFA Using Gradual RF Energy Delivery Mode With Octopus Electrodes | NCT04471272 | Radiofrequency ... Carcinoma, Hepa... | RFA using gradu... | 20 Years - 85 Years | Seoul National University Hospital | |
| Use of N-Acetylcysteine During Liver Procurement | NCT01394497 | Liver Failure Liver Failure, ... Liver Diseases Carcinoma, Hepa... Liver Neoplasms | N-acetylcystein | 18 Years - | Azienda Ospedaliera di Padova | |
| Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver | NCT01501240 | Liver Cirrhosis Carcinoma, Hepa... | 20 Years - 80 Years | Asan Medical Center | ||
| SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA | NCT05848947 | Carcinoma Carcinoma, Hepa... Liver Neoplasm | 99mTc-Macro Alb... | 18 Years - | Sirtex Medical | |
| Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation | NCT02631499 | Carcinoma, Hepa... Neoplastic Cell... | TACE Epirubicin lipiodol | 18 Years - 75 Years | Fudan University | |
| Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity | NCT02148562 | Hepatitis B Hepatitis B, Ch... End Stage Liver... Carcinoma, Hepa... | - | Universitaire Ziekenhuizen KU Leuven | ||
| A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area | NCT00913757 | Carcinoma, Hepa... Liver Cirrhosis... Hepatitis, Alco... Hepatitis, Chro... Hepatitis, Vira... | 18 Years - 90 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma | NCT01774344 | Carcinoma, Hepa... | Regorafenib (St... Placebo | 18 Years - | Bayer | |
| Phase II Study of Best Support Care (BSC) Plus ZD6474(Vandetanib) in Patients With Inoperable Hepatocellular Carcinoma (HCC) | NCT00508001 | Carcinoma, Hepa... | Vandetanib Vandetanib Best Supportive... | 20 Years - | Sanofi | |
| HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | NCT04618367 | Carcinoma, Hepa... Liver Neoplasms Sintilimab Portal Vein Tum... | Hepatic arteria... Lenvatinib Sintilimab | 18 Years - 75 Years | Sun Yat-sen University | |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas (TACE-KMG) | NCT01393197 | Carcinoma, Hepa... | Therapeutic Che... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of PTX-9908 Injection for Non-resectable HCC With TACE | NCT03812874 | Carcinoma, Hepa... | PTX-9908 Inject... Placebo | 20 Years - | TCM Biotech International Corp. | |
| A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma | NCT00440934 | Carcinoma, Hepa... | Amplitude-modul... | 18 Years - 95 Years | Pasche, Boris, M.D. | |
| Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | NCT00692770 | Carcinoma, Hepa... | Nexavar (Sorafe... Placebo | 18 Years - | Bayer | |
| Application of HBV Rapid Tests as a Tool for Wide-Use Screening | NCT01767597 | Hepatitis B Liver Cirrhosis Carcinoma, Hepa... | ELISA testing Rapid testing | 18 Years - | Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba | |
| A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma | NCT00554372 | Carcinoma, Hepa... | JX-594: Recombi... | 18 Years - | SillaJen, Inc. | |
| A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). | NCT00855218 | Carcinoma, Hepa... | Sorafenib (Nexa... Placebo | 18 Years - | Bayer | |
| Remote Ischemic Conditioning (RIC) in Recipients of Brain Death Donor Livers - A Feasibility and Safety Study | NCT02635347 | Liver Failure Carcinoma, Hepa... | Remote Ischemic... Pneumatic tourn... | 18 Years - | Rutgers, The State University of New Jersey | |
| Randomized Trial Comparing Stereotactic Body Radiation Therapy to Microwave Ablation for the Treatment of Localized Hepatocellular Carcinoma | NCT03168152 | Carcinoma, Hepa... | Microwave Ablat... Stereotactic Bo... | 18 Years - | University of Michigan Rogel Cancer Center | |
| Traditional (Traditional Chemoembolization) TACE Versus Microsphere TACE | NCT00936689 | Carcinoma, Hepa... | Selective TACE ... Selective tradi... | 18 Years - | University of Bologna | |
| RFA for Small HCC With No-touch Technique and Dual Cooled-Wet Electrode | NCT02806076 | Carcinoma, Hepa... | No-touch RFA ar... Conventional tu... | 20 Years - 85 Years | Seoul National University Hospital | |
| A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | NCT01897038 | Carcinoma, Hepa... | Onartuzumab Sorafenib | 18 Years - | Hoffmann-La Roche | |
| Fingerprint Characterization of Advanced HCC | NCT02372162 | Carcinoma, Hepa... | Image Fingerpri... Molecular Finge... | 18 Years - | University Hospital Tuebingen | |
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) | NCT00397540 | Carcinoma, Hepa... Chronic Hepatit... | PEIT RFTA | 19 Years - 80 Years | Seoul National University Hospital | |
| Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) | NCT01337492 | Carcinoma, Hepa... | Nexavar | 18 Years - | Case Comprehensive Cancer Center | |
| Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China | NCT01839630 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer | |
| Associating Liver Partition With Portal Vein Ligation For Staged Hepatectomy (ALPPS) or Portal Vein Occlusion in Treating Patients With Liver Cancer | NCT01722175 | Carcinoma, Hepa... | ALPPS surgery PVO surgery | 18 Years - | Washington University School of Medicine | |
| Assessment of Hepatitis B Virus Intra-host Population and Host-specific Immune Marker Diversity | NCT02148562 | Hepatitis B Hepatitis B, Ch... End Stage Liver... Carcinoma, Hepa... | - | Universitaire Ziekenhuizen KU Leuven | ||
| Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer | NCT00920192 | Carcinoma, Hepa... | Foretinib | 18 Years - | GlaxoSmithKline | |
| TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | NCT04560751 | Carcinoma, Hepa... | Lenvatinib TACE | 18 Years - 75 Years | Zhejiang Cancer Hospital | |
| MiRNA as a Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma | NCT02448056 | Carcinoma, Hepa... Marker, Biologi... | 20 Years - | National Taiwan University Hospital | ||
| The Role of Low Molecular Weight Heparins in Hepatocellular Carcinoma | NCT00827554 | Hepatocellular ... | LMWH TACE | 18 Years - 75 Years | Eastern Hepatobiliary Surgery Hospital | |
| Pembrolizumab and Lenvatinib for Resectable Hepatocellular Carcinoma | NCT05389527 | Carcinoma, Hepa... | Pembrolizumab+L... | 18 Years - | Shanghai Zhongshan Hospital | |
| SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma | NCT00503867 | Carcinoma, Hepa... Hepatoma | SIR-Spheres mic... | 18 Years - | Sirtex Medical | |
| Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC | NCT02018757 | Carcinoma, Hepa... | TACE containing... TACE containing... | 18 Years - 75 Years | First Hospital of China Medical University | |
| A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer | NCT00563095 | Carcinoma, Hepa... | Transcatheter A... Transcatheter A... | 18 Years - | Hospital Authority, Hong Kong | |
| Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | NCT01009593 | Hepatocellular ... Hepatocellular ... Carcinoma, Hepa... Liver Diseases Neoplasms by Hi... Digestive Syste... Carcinoma Liver Neoplasms Neoplasms Neoplasms by Si... Digestive Syste... Adenocarcinoma Neoplasms, Glan... | ABT-869 Sorafenib | 18 Years - | Abbott | |
| Arsenic Trioxide TACE and Intravenous Administration in Unresectable Hepatocellular Carcinoma | NCT01861912 | Carcinoma, Hepa... | Arsenic trioxid... Arsenic trioxid... lipiodol NaCl solution | 18 Years - 75 Years | Guangdong Provincial People's Hospital | |
| A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | NCT01441388 | Carcinoma, Rena... Glioblastoma Carcinoma, Hepa... | Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... Crizotinib plus... | 18 Years - | Pfizer | |
| Transcatheter Arterial Chemoembolization With KMG Microsphere Treating Advance-stage Hepatocellular Carinomas | NCT01393093 | Carcinoma, Hepa... | Therapeutic Che... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| A Study of GPC3-targeted T Cells by Intratumor Injection for Advanced HCC (GPC3-CART) | NCT03130712 | Carcinoma, Hepa... | GPC3-CART cells | 18 Years - 69 Years | Shanghai GeneChem Co., Ltd. | |
| GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start | NCT01191385 | Carcinoma, Hepa... | Any treatment f... | 18 Years - | Bayer | |
| Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety | NCT01908322 | Carcinoma, Hepa... | Sorafenib (Nexa... | - | Bayer |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
